在生物标志物阳性的无症状个体中诊断阿尔茨海默病

IF 10.6 1区医学 Q1 CLINICAL NEUROLOGY

Brain Pub Date : 2025-04-28 DOI:10.1093/brain/awaf162

Nunzio Pomara, Bruno Pietro Imbimbo

引用次数: 0

摘要

大约25%的认知功能未受损的老年人的脑淀粉样蛋白负担升高，与有症状的阿尔茨海默病患者相当。Pomara和Imbimbo研究了正在进行的争论，即这些人是否应该被归类为患有临床前阿尔茨海默病，还是仅仅被认为是“有风险”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Making a diagnosis of Alzheimer's disease in asymptomatic individuals with positive biomarkers

About 25% of cognitively unimpaired older adults have an elevated brain amyloid burden comparable to that of individuals with symptomatic Alzheimer’s disease. Pomara and Imbimbo examine the ongoing debate over whether these individuals should be classified as having preclinical Alzheimer’s disease or simply be considered ‘at risk’.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Brain 医学-临床神经学

CiteScore

20.30

自引率

4.10%

发文量

458

审稿时长

3-6 weeks

期刊介绍： Brain, a journal focused on clinical neurology and translational neuroscience, has been publishing landmark papers since 1878. The journal aims to expand its scope by including studies that shed light on disease mechanisms and conducting innovative clinical trials for brain disorders. With a wide range of topics covered, the Editorial Board represents the international readership and diverse coverage of the journal. Accepted articles are promptly posted online, typically within a few weeks of acceptance. As of 2022, Brain holds an impressive impact factor of 14.5, according to the Journal Citation Reports.